Static Chart Vaxcyte, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-16 pm EST			5-day change	1st Jan Change
43.67 ^USD	-1.51%		-5.44%	-46.65%

Dec. 08	Vaxcyte Doses First Patients in Phase 3 Trial of VAX-31 in Invasive Pneumococcal Disease, Pneumonia	MT
Dec. 08	Vaxcyte says topline results from OPUS trial expected in Q4 2026	RE

Duration

Period